A Phase 2/3 interventional study of Evolocumab in Severe Familial Hypercholesterolemia, sponsored by Amgen. Completed at 44 sites in 18 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-28.
Sponsored by Amgen · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 25th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2012, is one of 4 in phase 2/3, and was the 26th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Wisconsin, Madison · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 6–17
Brigham and Women's Hospital · Sites in United States
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 12 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 34 · Phase 4 4
First in 1985; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 163 across the 68 interventional studies, 22 across the 8 observational. Of the 57 that completed or were terminated, 32 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 76 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 6 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperlipoproteinemia Type II with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05284513Geisinger ClinicCollaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) | 2027-01 |
| NCT05750667Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia | 2027-02-28 |
| NCT07919353Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 | 2027-02-28 |
| NCT06743659Brigham and Women's HospitalComputerized Decision Support for Identification and Management of Familial Hypercholesterolemia | 2027-03-30 |
| NCT06439654Atlantic Health SystemAtlantic Lipid Lowering Treatment Optimization Program | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to assess the long term safety and tolerability of evolocumab (AMG 145) in adolescents and adults with severe familial hypercholesterolemia.
This phase 2/3 open-label extension study was designed to characterize the safety and tolerability of long-term administration of evolocumab to adults and adolescents with severe FH (HoFH or non-HoFH severe FH). Participants not on lipid apheresis at enrollment or within the prior 8 weeks initiated treatment with evolocumab 420 mg once monthly (QM). Participants on lipid apheresis at enrollment initiated treatment with evolocumab 420 mg once every 2 weeks (Q2W). Dose frequency changes (420 mg QM vs 420 mg Q2W) were permitted at week 12, 24, or other visits with Sponsor approval. Participants with \< 5% LDL-C reduction from baseline and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) \< 100 ng/mL could discontinue evolocumab. If serum unbound PCSK9 was ≥ 100 ng/mL with QM dosing, the participant could switch to evolocumab 420 mg Q2W treatment. Participants on apheresis with ≥ 5% LDL-C reduction from baseline and serum unbound PCSK9 \< 100 ng/mL with Q2W treatment could switch to QM dosing.
Participants were to continue to receive open-label evolocumab for up to 5 years or until evolocumab became commercially available in the relevant patient population, whichever occurred first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
Biological: Evolocumab
Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
Also known as: AMG 145, Repatha
Number of Participants With Adverse Events
The severity of each adverse event (AE) was graded according to the National Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE) grading scale, where grade 1 = mild AE, grade 2 = moderate AE, grade 3 = severe AE, grade 4 = life-threatening AE and grade 5 = death due to AE.
Time frame: From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months.
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percent Change From Baseline in Lipoprotein (a)
Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percent Change From Baseline in Apolipoprotein B
Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio
Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio
Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percentage of Participants With a 15% or Greater Reduction in LDL-C
Time frame: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Participants were enrolled at 43 centers in Canada, South Africa, Czech Republic, Netherlands, USA, France, Spain, Italy, Belgium, Australia, New Zealand, United Kingdom, Japan, Israel, Greece, Lebanon, Brazil, and Hong Kong between 01 June 2012 and 19 March 2015.
| Milestone | HoFH | Severe FH |
|---|---|---|
| Started | 106 | 194 |
| Completed | 74 | 178 |
| Not completed | 32 | 16 |
| Withdrew: Withdrawal by subject | 14 | 4 |
| Withdrew: Death | 3 | 6 |
| Withdrew: Study closure | 12 | 6 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Other | 1 | 0 |
The severity of each adverse event (AE) was graded according to the National Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE) grading scale, where grade 1 = mild AE, grade 2 = moderate AE, grade 3 = severe AE, grade 4 = life-threatening AE and grade 5 = death due to AE.
| Participants | HoFH | Severe FH |
|---|---|---|
| All adverse events (AEs) | 94 | 174 |
| Adverse events ≥ grade 2 | 76 | 143 |
| Adverse events ≥ grade 3 | 38 | 68 |
| Adverse events ≥ grade 4 | 4 | 14 |
| Serious adverse events (SAEs) | 29 | 57 |
| AEs Leading to discontinuation of evolocumab | 3 | 8 |
| Fatal adverse events | 2 | 5 |
| Device-related adverse events | 6 | 18 |
| percent change | HoFH | Severe FH |
|---|---|---|
| Week 4 | -20.42 (-38.25 to -8.28) | -54.95 (-66.67 to -44.55) |
| Week 6 | -18.32 (-36.09 to -4.16) | -67.57 (-79.54 to -53.93) |
| Week 8 | -20.28 (-37.81 to -8.44) | -55.03 (-68.58 to -42.07) |
| Week 12 | -18.26 (-36.06 to -7.76) | -57.11 (-68.00 to -42.80) |
| Week 16 | -23.15 (-39.23 to -7.87) | -57.53 (-67.99 to -44.95) |
| Week 20 | -25.37 (-45.99 to -8.96) | -57.26 (-67.48 to -44.68) |
| Week 24 | -21.84 (-41.39 to -8.11) | -57.10 (-67.05 to -43.70) |
| Week 36 | -26.79 (-46.44 to -8.28) | -56.08 (-68.70 to -44.47) |
| Week 48 | -25.50 (-44.79 to -4.43) | -59.67 (-69.14 to -47.88) |
| Week 60 | -27.26 (-44.58 to -4.28) | -57.13 (-68.42 to -42.65) |
| Week 72 | -27.11 (-51.06 to -12.03) | -55.73 (-70.52 to -42.76) |
| Week 84 | -27.96 (-50.29 to -7.96) | -56.02 (-68.49 to -42.18) |
| Week 96 | -22.47 (-46.53 to -8.12) | -57.10 (-69.53 to -41.66) |
| Week 108 | -26.15 (-44.58 to -5.62) | -60.57 (-69.47 to -43.15) |
| Week 120 | -26.66 (-43.43 to -7.42) | -56.76 (-69.48 to -41.70) |
| Week 132 | -28.25 (-48.23 to -9.42) | -55.25 (-68.17 to -39.89) |
| Week 144 | -28.33 (-49.27 to -10.33) | -56.48 (-69.26 to -40.69) |
| Week 156 | -23.65 (-47.66 to -11.05) | -55.38 (-69.48 to -41.03) |
| Week 168 | -29.52 (-51.35 to -4.41) | -54.77 (-67.16 to -36.42) |
| Week 180 | -25.66 (-53.71 to -9.87) | -54.08 (-71.53 to -37.55) |
| Week 192 | -30.12 (-53.23 to -11.81) | -52.19 (-66.79 to -33.99) |
| Week 204 | -29.62 (-47.43 to -6.11) | -59.59 (-70.50 to -39.06) |
| Week 216 | -32.22 (-46.65 to -8.97) | -50.62 (-67.73 to -32.31) |
| percent change | HoFH | Severe FH |
|---|---|---|
| Week 4 | -19.62 (-35.54 to -7.84) | -50.00 (-59.92 to -39.88) |
| Week 6 | -18.17 (-33.88 to -4.29) | -59.76 (-70.50 to -49.23) |
| Week 8 | -20.29 (-35.94 to -9.28) | -50.61 (-58.49 to -37.91) |
| Week 12 | -17.05 (-32.03 to -6.99) | -50.25 (-61.49 to -38.63) |
| Week 16 | -21.73 (-37.81 to -7.88) | -51.31 (-59.76 to -40.40) |
| Week 20 | -24.09 (-43.06 to -7.76) | -50.76 (-59.44 to -38.67) |
| Week 24 | -21.88 (-38.81 to -9.54) | -51.12 (-60.67 to -38.52) |
| Week 36 | -22.43 (-44.08 to -6.22) | -49.65 (-61.00 to -38.26) |
| Week 48 | -24.08 (-43.47 to -3.98) | -51.12 (-61.58 to -42.11) |
| Week 60 | -24.81 (-42.96 to -2.67) | -49.73 (-61.61 to -38.00) |
| Week 72 | -25.88 (-48.21 to -9.47) | -48.94 (-61.14 to -36.08) |
| Week 84 | -21.00 (-42.68 to -7.45) | -49.50 (-62.07 to -35.14) |
| Week 96 | -21.10 (-42.84 to -7.85) | -49.53 (-63.80 to -36.86) |
| Week 108 | -24.17 (-43.01 to -5.69) | -52.86 (-61.20 to -38.11) |
| Week 120 | -23.21 (-40.37 to -6.23) | -49.45 (-60.48 to -35.91) |
| Week 132 | -26.39 (-40.28 to -7.19) | -49.49 (-60.95 to -33.66) |
| Week 144 | -25.38 (-45.55 to -8.08) | -49.81 (-61.69 to -33.88) |
| Week 156 | -22.35 (-45.47 to -10.50) | -50.15 (-60.81 to -36.11) |
| Week 168 | -27.97 (-48.82 to -4.36) | -47.93 (-60.71 to -31.01) |
| Week 180 | -26.32 (-49.82 to -8.62) | -48.43 (-62.22 to -33.06) |
| Week 192 | -27.61 (-49.49 to -9.29) | -44.50 (-57.71 to -29.77) |
| Week 204 | -27.22 (-45.14 to -5.73) | -50.84 (-64.12 to -36.03) |
| Week 216 | -31.40 (-42.75 to -9.67) | -45.30 (-61.45 to -26.32) |
| percent change | HoFH | Severe FH |
|---|---|---|
| Week 4 | -11.11 (-27.50 to 0.0) | -20.49 (-39.84 to -11.61) |
| Week 6 | -8.97 (-24.21 to 3.76) | -24.42 (-45.95 to -9.38) |
| Week 8 | -9.95 (-25.00 to 3.23) | -21.51 (-39.84 to -9.09) |
| Week 12 | -7.69 (-21.64 to 6.83) | -24.40 (-40.28 to -9.09) |
| Week 16 | -8.93 (-25.00 to 4.76) | -23.08 (-38.88 to -7.62) |
| Week 20 | -13.52 (-29.36 to 0.00) | -22.21 (-39.34 to -5.98) |
| Week 24 | -10.46 (-23.75 to 1.00) | -25.99 (-41.81 to -9.09) |
| Week 36 | -15.14 (-28.18 to 0.00) | -24.26 (-41.30 to -7.85) |
| Week 48 | -13.17 (-30.51 to 0.00) | -26.32 (-41.94 to -10.49) |
| Week 60 | -13.04 (-35.00 to 2.86) | -24.05 (-41.97 to -7.63) |
| Week 72 | -17.43 (-37.19 to 5.88) | -24.23 (-43.96 to -6.81) |
| Week 84 | -14.12 (-36.73 to 0.63) | -24.12 (-44.05 to -8.02) |
| Week 96 | -17.24 (-33.33 to 0.49) | -31.28 (-47.33 to -13.34) |
| Week 108 | -21.43 (-42.50 to 0.00) | -32.44 (-48.65 to -12.69) |
| Week 120 | -20.16 (-33.25 to 0.00) | -31.22 (-45.00 to -11.40) |
| Week 132 | -19.15 (-37.68 to 0.00) | -29.32 (-49.82 to -12.29) |
| Week 144 | -23.64 (-47.06 to 0.00) | -30.36 (-48.17 to -11.92) |
| Week 156 | -18.40 (-42.14 to -2.33) | -28.10 (-47.35 to -9.09) |
| Week 168 | -22.94 (-41.01 to -0.49) | -23.96 (-45.64 to -9.09) |
| Week 180 | -17.29 (-43.83 to 0.00) | -26.23 (-46.01 to -8.83) |
| Week 192 | -22.78 (-44.44 to 0.00) | -20.00 (-37.75 to -2.44) |
| Week 204 | -16.33 (-38.46 to 3.95) | -14.29 (-34.38 to 10.00) |
| Week 216 | -14.06 (-36.07 to 4.08) | -0.67 (-23.64 to 23.81) |
| percent change | HoFH | Severe FH |
|---|---|---|
| Week 4 | -16.91 (-31.67 to -6.81) | -43.84 (-54.59 to -34.40) |
| Week 6 | -16.25 (-27.82 to -1.96) | -56.70 (-67.23 to -46.11) |
| Week 8 | -17.57 (-32.00 to -6.24) | -43.95 (-55.69 to -31.55) |
| Week 12 | -13.11 (-26.87 to -3.49) | -45.78 (-55.16 to -32.65) |
| Week 16 | -18.65 (-34.77 to -8.35) | -45.72 (-55.23 to -35.39) |
| Week 20 | -22.60 (-39.05 to -5.03) | -45.16 (-53.93 to -33.18) |
| Week 24 | -20.09 (-33.04 to -3.97) | -44.87 (-55.32 to -31.01) |
| Week 36 | -16.48 (-36.43 to -2.56) | -43.33 (-55.12 to -29.10) |
| Week 48 | -15.90 (-33.60 to -4.15) | -45.38 (-55.40 to -33.93) |
| Week 60 | -15.99 (-38.12 to -0.27) | -44.81 (-56.07 to -31.33) |
| Week 72 | -20.70 (-42.02 to -3.17) | -44.07 (-55.61 to -32.72) |
| Week 84 | -19.52 (-35.66 to -0.09) | -43.87 (-55.50 to -32.13) |
| Week 96 | -15.07 (-36.34 to -3.67) | -42.31 (-57.65 to -29.89) |
| Week 108 | -19.45 (-36.07 to 5.03) | -46.30 (-55.41 to -32.21) |
| Week 120 | -21.58 (-33.33 to -1.57) | -44.33 (-54.68 to -30.00) |
| Week 132 | -22.44 (-35.70 to -3.75) | -43.48 (-54.90 to -28.22) |
| Week 144 | -21.24 (-41.89 to -3.55) | -41.64 (-54.36 to -27.85) |
| Week 156 | -18.30 (-36.66 to -5.63) | -44.04 (-55.16 to -29.73) |
| Week 168 | -20.38 (-41.58 to -2.81) | -40.20 (-52.22 to -25.78) |
| Week 180 | -19.51 (-39.73 to -3.02) | -41.58 (-54.70 to -24.57) |
| Week 192 | -19.38 (-39.63 to -2.63) | -37.02 (-52.06 to -21.08) |
| Week 204 | -21.64 (-36.15 to -5.48) | -43.19 (-56.81 to -28.81) |
| Week 216 | -22.68 (-35.34 to -4.51) | -35.95 (-53.05 to -23.95) |
| percent change | HoFH | Severe FH |
|---|---|---|
| Week 4 | -21.32 (-38.45 to -10.36) | -43.49 (-53.07 to -33.78) |
| Week 6 | -23.25 (-35.54 to -7.14) | -52.38 (-60.97 to -42.29) |
| Week 8 | -23.93 (-35.26 to -5.42) | -43.44 (-51.21 to -34.81) |
| Week 12 | -21.20 (-34.98 to -9.31) | -44.75 (-53.20 to -35.12) |
| Week 16 | -24.01 (-36.52 to -8.86) | -45.31 (-52.38 to -34.95) |
| Week 20 | -24.69 (-36.39 to -4.29) | -43.07 (-51.89 to -33.54) |
| Week 24 | -23.53 (-38.59 to -9.10) | -43.79 (-52.96 to -34.28) |
| Week 36 | -27.16 (-42.86 to -9.12) | -42.69 (-53.01 to -30.99) |
| Week 48 | -26.54 (-43.73 to -8.03) | -44.68 (-54.47 to -33.90) |
| Week 60 | -22.80 (-45.57 to -5.13) | -43.82 (-54.01 to -32.46) |
| Week 72 | -24.79 (-42.72 to -9.47) | -42.64 (-54.28 to -30.73) |
| Week 84 | -22.62 (-41.45 to -6.24) | -43.16 (-53.15 to -27.42) |
| Week 96 | -23.00 (-38.97 to -10.33) | -42.46 (-54.03 to -31.69) |
| Week 108 | -25.03 (-41.12 to -4.98) | -43.68 (-53.91 to -32.90) |
| Week 120 | -25.40 (-42.55 to -6.92) | -42.42 (-54.18 to -30.87) |
| Week 132 | -25.66 (-41.29 to -5.10) | -42.14 (-53.54 to -30.15) |
| Week 144 | -27.79 (-44.96 to -6.39) | -43.40 (-54.91 to -28.80) |
| Week 156 | -25.52 (-45.62 to -9.87) | -43.85 (-53.49 to -29.86) |
| Week 168 | -26.30 (-46.28 to -8.75) | -41.59 (-52.67 to -24.39) |
| Week 180 | -29.53 (-47.74 to -7.54) | -40.13 (-54.50 to -28.99) |
| Week 192 | -27.79 (-47.16 to -12.15) | -38.24 (-53.80 to -25.34) |
| Week 204 | -27.32 (-42.19 to -7.20) | -43.13 (-57.50 to -31.50) |
| Week 216 | -30.92 (-42.09 to -8.93) | -40.78 (-52.60 to -26.46) |
| percent change | HoFH | Severe FH |
|---|---|---|
| Week 4 | -23.06 (-39.88 to -6.22) | -46.79 (-57.95 to -37.69) |
| Week 6 | -21.38 (-36.90 to -10.11) | -59.77 (-68.35 to -48.98) |
| Week 8 | -21.53 (-36.51 to -4.66) | -47.82 (-57.87 to -37.07) |
| Week 12 | -16.67 (-30.72 to -4.37) | -48.63 (-59.21 to -38.16) |
| Week 16 | -22.52 (-42.86 to -8.97) | -48.98 (-58.13 to -39.59) |
| Week 20 | -25.41 (-41.87 to -12.43) | -49.12 (-57.11 to -38.09) |
| Week 24 | -22.97 (-38.08 to -8.99) | -49.92 (-58.44 to -37.29) |
| Week 36 | -26.86 (-41.04 to -7.69) | -49.02 (-58.10 to -35.67) |
| Week 48 | -25.96 (-43.38 to -12.26) | -49.35 (-59.34 to -38.98) |
| Week 60 | -24.31 (-44.46 to -6.67) | -48.57 (-59.11 to -35.94) |
| Week 72 | -23.63 (-45.15 to -10.89) | -48.94 (-60.36 to -38.76) |
| Week 84 | -24.09 (-43.12 to -4.16) | -49.47 (-59.73 to -34.54) |
| Week 96 | -24.75 (-45.92 to -8.61) | -48.45 (-60.40 to -36.17) |
| Week 108 | -26.03 (-41.27 to -4.78) | -50.18 (-60.18 to -37.84) |
| Week 120 | -26.45 (-44.21 to -12.32) | -49.75 (-59.38 to -36.17) |
| Week 132 | -24.26 (-47.15 to -7.81) | -48.54 (-58.39 to -32.01) |
| Week 144 | -28.09 (-48.50 to -7.81) | -47.44 (-59.12 to -33.82) |
| Week 156 | -27.21 (-46.95 to -12.25) | -49.10 (-59.29 to -35.31) |
| Week 168 | -32.16 (-47.39 to -12.53) | -44.46 (-56.03 to -30.06) |
| Week 180 | -28.70 (-48.45 to -9.71) | -45.13 (-58.67 to -30.84) |
| Week 192 | -27.50 (-50.49 to -10.22) | -43.40 (-56.45 to -28.14) |
| Week 204 | -28.04 (-46.84 to -12.13) | -49.71 (-60.22 to -35.16) |
| Week 216 | -28.37 (-41.15 to -11.76) | -44.00 (-56.69 to -31.29) |
| percentage of participants | HoFH | Severe FH |
|---|---|---|
| Week 4 | 62.1 | 98.9 |
| Week 6 | 51.8 | 98.2 |
| Week 8 | 57.4 | 97.9 |
| Week 12 | 56.7 | 99.0 |
| Week 16 | 63.7 | 97.3 |
| Week 20 | 64.4 | 98.9 |
| Week 24 | 66.7 | 96.3 |
| Week 36 | 62.8 | 97.3 |
| Week 48 | 60.2 | 97.9 |
| Week 60 | 60.2 | 94.1 |
| Week 72 | 69.4 | 94.0 |
| Week 84 | 65.9 | 93.9 |
| Week 96 | 65.9 | 94.4 |
| Week 108 | 61.0 | 96.1 |
| Week 120 | 64.6 | 91.8 |
| Week 132 | 61.7 | 92.7 |
| Week 144 | 72.2 | 93.3 |
| Week 156 | 68.8 | 93.4 |
| Week 168 | 59.2 | 93.6 |
| Week 180 | 63.5 | 93.4 |
| Week 192 | 66.2 | 91.8 |
| Week 204 | 65.3 | 93.8 |
| Week 216 | 70.6 | 88.5 |
Collected over Adverse events are reported from the first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months. Deaths are reported from the first dose of study drug up to the end of study visit date.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HoFH | 3/106 (2.8%) | 29/106 (27.4%) | 80/106 (75.5%) |
| Severe FH | 6/194 (3.1%) | 57/194 (29.4%) | 134/194 (69.1%) |
| Total | 9/300 (3%) | 86/300 (28.7%) | 214/300 (71.3%) |
| Event | HoFH | Severe FH | Total |
|---|---|---|---|
| Angina pectorisCardiac disorders | 4/106 | 7/194 | 11/300 |
| Coronary artery diseaseCardiac disorders | 3/106 | 1/194 | 4/300 |
| Aortic stenosisVascular disorders | 3/106 | 2/194 | 5/300 |
| Chest painGeneral disorders | 1/106 | 5/194 | 6/300 |
| Myocardial ischaemiaCardiac disorders | 1/106 | 4/194 | 5/300 |
| Acute myocardial infarctionCardiac disorders | 2/106 | 2/194 | 4/300 |
| Alanine aminotransferase increasedInvestigations | 2/106 | 0/194 | 2/300 |
| Angina unstableCardiac disorders | 0/106 | 3/194 | 3/300 |
| Non-cardiac chest painGeneral disorders | 1/106 | 3/194 | 4/300 |
| CholelithiasisHepatobiliary disorders | 0/106 | 2/194 | 2/300 |
| Event | HoFH | Severe FH | Total |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 17/106 | 36/194 | 53/300 |
| Upper respiratory tract infectionInfections and infestations | 18/106 | 17/194 | 35/300 |
| InfluenzaInfections and infestations | 17/106 | 21/194 | 38/300 |
| HeadacheNervous system disorders | 17/106 | 16/194 | 33/300 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/106 | 24/194 | 30/300 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/106 | 23/194 | 29/300 |
| DiarrhoeaGastrointestinal disorders | 7/106 | 22/194 | 29/300 |
| FatigueGeneral disorders | 8/106 | 19/194 | 27/300 |
| AnxietyPsychiatric disorders | 10/106 | 0/194 | 10/300 |
| Back painMusculoskeletal and connective tissue disorders | 9/106 | 17/194 | 26/300 |
All enrolled participants. Baseline data for parent study rollover participants are defined at the parent study baseline.
| Age, Categorical(Participants) | HoFH | Severe FH | Total |
|---|---|---|---|
| <=18 years | 14 | 0 | 14 |
| Between 18 and 65 years | 88 | 152 | 240 |
| >=65 years | 4 | 42 | 46 |
| Age, Continuous(years) | HoFH | Severe FH | Total |
|---|---|---|---|
| Mean | 34.3 ± 14.4 | 54.7 ± 11.9 | 47.5 ± 16.1 |
| Sex: Female, Male(Participants) | HoFH | Severe FH | Total |
|---|---|---|---|
| Female | 54 | 78 | 132 |
| Male | 52 | 116 | 168 |
| Ethnicity (NIH/OMB)(Participants) | HoFH | Severe FH | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 22 | 27 |
| Not Hispanic or Latino | 101 | 172 | 273 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | HoFH | Severe FH | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 13 | 3 | 16 |
| Black or African American | 0 | 6 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 85 | 179 | 264 |
| Other | 7 | 4 | 11 |
| Mixed Race | 0 | 2 | 2 |
| Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | HoFH | Severe FH | Total |
|---|---|---|---|
| Mean | 329.0 ± 136.7 | 192.7 ± 64.6 | 240.9 ± 116.3 |
| Non-high-density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | HoFH | Severe FH | Total |
|---|---|---|---|
| Mean | 350.5 ± 138.4 | 222.1 ± 68.3 | 267.5 ± 116.3 |
| Lipoprotein (a) Concentration(nmol/L) | HoFH | Severe FH | Total |
|---|---|---|---|
| Mean | 104.7 ± 100.6 | 127.1 ± 142.8 | 119.2 ± 129.7 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2012 to primary completion in May 2018, 71 months.
Results were first posted in Jan 2019, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab
Hyperlipoproteinemia Type II →